New diterpenoids and the bioactivity of Erythrophleum fordii

Chuan-Chung Tsao a, Yuh-Chiang Shen b, Chung-Ren Su a, Chia-Ying Li a, Meei-Jen Liou c, Nguyen-Xuan Dung d, Tian-Shung Wu a,c,**

a Department of Chemistry, National Cheng Kung University, No. 1 University Road, Tainan 701, Taiwan
b National Research Institute of Chinese Medicine, Taipei 112, Taiwan
c Department of Applied Chemistry, Providence University, Taichung 433, Taiwan
d Department of Chemistry, College of Natural Sciences, Hanoi National University, Hanoi 10000, Vietnam

A R T I C L E   I N F O
Article history:
Received 11 July 2008
Revised 7 September 2008
Accepted 9 September 2008
Available online 12 September 2008

Keywords:
Erythrophleum fordii Oliv
Cassaine-type diterpenoids
Anti-inflammatory activity

A B S T R A C T
A phytochemical investigation of the leaves of Erythrophleum fordii Oliv. has led to the isolation of three new cassaine-type diterpenoids, erythrofordin A (1), erythrofordin B (2) and erythrofordin C (3), as well as a norcassaine diterpenoid with a novel skeleton, norerythrofordin A (4), and 27 known compounds (5–31). The structures of 1–4 were elucidated on the basis of spectroscopic analysis. Selected compounds from this plant were examined for anti-inflammatory activity. Taraxerol (16) displayed potent NO-reducing activity in microglial cells, and gallic acid (27) exhibited excellent DPPH radical-scavenging effects.

Crown Copyright © 2008 Published by Elsevier Ltd. All rights reserved.

1. Introduction

Erythrophleum fordii Oliver (Leguminosae) is widely distributed in China, Taiwan, and Vietnam. It is used as a Chinese traditional medicine, primarily for invigoration and promotion of blood circulation.1 In prior studies on the genus, Erythrophleum, cassaine diterpenoid amines and amides were found as the main constituents,2–4 with minor amounts of cassaine acids also present.5 To our knowledge, few chemical and pharmacological investigations have been reported on E. fordii. We report herein the isolation and structure elucidation of compounds from this species, including three new cassaine-type diterpenoids, erythrofordin A–C (1–3), a norcassaine diterpenoid with a novel skeleton, norerythrofordin A (4), and 27 known compounds, including 13 triterpenoids (5–17), five steroids (18–22) and miscellaneous structure types (23–31) (see Table 1).

2. Chemistry

Air-dried, powdered whole plants of E. fordii were extracted with MeOH at room temperature. The solvent was evaporated and then the resulting residue was partitioned between CHCl3 and H2O. The CHCl3 fraction was chromatographed on a silica gel column using CHCl3/MeOH gradients to furnish three new cassa-

ine-type diterpenoids (1–3), a norcassaine diterpenoid with a novel skeleton (4), and 27 known compounds (5–31).

Erythrofordin A (1) was obtained as colorless needle, mp 138–139 °C. HRFABMS of 1 exhibited a pseudomolecular ion peak at m/z 395.2068, consistent with the molecular formula C21H30O7.

IR absorption bands at 3381, 1726, 1709, and 1642 cm−1 were assignable to hydroxyl and carbonyl functions. The 1H NMR spectrum showed three methyl groups at δ 0.67 (3 H, s), 1.18 (3 H, d, J = 8.7 Hz) and 1.37 (3 H, s), a methoxy group at δ 3.76 (3 H, s), and an olefinic proton at δ 5.77 (1 H, s). The 13C NMR spectrum revealed three carbonyl signals at δ 207.8, 174.2 and 169.5, and a pair of olefinic carbons at δ 167.7 and 112.6, which indicated the presence of a cassaine-type diterpenoid with a β-carbomethoxy group at C-4.6 Evidence for the 6-keto-7β-hydroxy group was provided by the H-7ν signal at δ 3.93 (1 H, d, J = 10.6 Hz) and the H-5 signal at δ 2.34 (1 H, s), which was confirmed by HMBC correlations of H-5 (δ 2.34) with C-6 (δ 207.8) and H-7 (δ 3.93) with C-8 (δ 50.8) in the HMBC spectrum. Another oxygen-substituted methine signal appeared at δ 3.36 (1 H, dd, J = 11.6, 4.2 Hz), which correlated with a carbon resonance at δ 78.1 in the HMQC spectrum. From these data, we postulated the presence of a hydroxyl group at C-3, which was supported by correlations in the HMBC spectrum between the proton at δ 1.37 (3 H, s, H-18) and the carbon at δ 78.1 (C-3). The position of a β-carbomethoxy moiety was also confirmed by HMBC correlations between both H-5 (δ 2.34) and H-18 (δ 1.37) with C-19 (δ 174.2). The α,β-conjugated acid moiety in 1 was found to be linked to C-13, based on HMBC correlations between the H-15 proton (δ 5.77) and the C-16 (δ 169.5) and C-12 (δ 23.7) carbons. The
relative configuration of 1 was assigned on the basis of a NOESY experiment. NOE correlations were found between H-3 (δ 3.36) and H-18 (δ 1.37), H-18 (δ 1.37) and H-5 (δ 2.34) and H-5 (δ 3.93), indicating that these groups are located on the α-face. The double bond at C-13 and C-15 was assigned as the Z-form, which was confirmed by NOE correlation between H-15 (δ 5.77) and H-14 (δ 2.85). Thus, the structure of 1 was proposed as shown, and this compound has been named erythrofordin A (1).

Erythrofordin B (2) was isolated as optically colorless syrup. The molecular formula of 2 was determined as C35H30O14 by HRMS. The IR spectrum displayed absorptions at 3379, 1716, and 1772 cm⁻¹, due to hydroxyl and carbonyl groups. Comparison of the 1H and 13C NMR spectra of 2 with those of 1 revealed these compounds to be similar, with the major difference being the appearance of an additional acetoxy group (δH 1.95 and δC 177.5, 22.2) in 2. This acetoxy group was positioned at C-7, based on HMBC correlation between δH 4.03 (1H, d, J = 9.7 Hz, H-7) and δC 177.5 (C-12), as well as NOE correlation between δH 1.95 (H-23) and 1.17 (H-17). Assignment of the relative stereochemistry of 2 was also accomplished based on data from a NOESY spectrum and confirmed H-3, H-18, H-5, H-7, and H-17 to be on the α-face. However, the C13–C15 double bond of 2 has an E- rather than Z-configuration, which was determined by NOE correlation between H-15 (δ 5.60) and H-12 (δ 2.15). From the above spectroscopic data, the structure of 2 was fully determined, and this compound has been named erythrofordin B (2).

Erythrofordin C (3) was obtained as optically colorless syrup and had the molecular formula C35H30O14 as established by HRFABMS. IR absorption bands were observed at 3418, 1702, and 1645 cm⁻¹, attributed to hydroxyl and carbonyl groups. The 1H and 13C NMR data showed the presence of characteristic signals for three methyl groups, a methoxy group, an olefinic proton and seven corresponding carbon signals at δ 211.5, 176.2, 176.6, 153.2, 121.7, 76.5, and 79.1, which suggested that, like 1, 3 is also a cassaine-type diterpenoid with a β-carbomethoxy group at C-4.

Compared with 1, the H-5 proton signal was shifted upfield to δ 1.45 (1H, d, J = 12.2 Hz) and coupled with the proton at δ 4.50 (1H, dd, J = 12.2, 0.9 Hz, H-6). Thus, the hydroxyl group was assigned at C-6 and the carbonyl group at C-7. These assignments were further supported by HMBC correlations of H-5 (δ 1.45) with C-6 (δ 76.5) and H-6 (δ 4.50) with C-7 (δ 211.5) in the HMBC spectrum of 3. The relative stereochemistry of 3 was determined from NOESY correlations between H-3 (δ 3.22), H-5 (δ 1.45) and H-18 (δ 1.63), indicating H-3 and H-18 are α-configured. In addition, H-20 (δ 1.01), H-6 (δ 4.50), and H-8 (δ 2.47) also showed NOESY correlations, which suggests that H-6 and H-8 are β-configured. The double bond at C-13 and C-15 is in the Z-form, as indicated by NOE correlations between H-15 (δ 5.71) and H-14 (δ 2.87). Thus, the structure of 3 was fully determined, and the compound was named erythrofordin C.

Norerythrofordin A (4) was isolated as optically colorless needle, mp 250–251°C. The HREIMS of 4 showed a peak at m/z 336.993 corresponding to the molecular formula C19H24O8, and 19 carbon signals were observed in the 13C NMR spectrum. IR absorption bands at 3408, 1702, and 1645 cm⁻¹ were assignable to hydroxyl and carbonyl functions. The 1H and 13C NMR spectra of 4 and 1 were similar, except for the absence of signals for a carbomethoxy group in 4. The presence of H-4 in 4 was confirmed by the presence of a doublet at δ 0.84 (3H, J = 6.0 Hz, H-4), and further identified by HMBC correlations of H-18 (δ 0.84) with C-3 (δ 73.9), C-4 (δ 33.4) and C-5 (δ 59.2) in the HMBC spectrum. In the assignment of the stereochemistry of 4, NOESY crosspeaks for H-3 with H-18, H-18 with H-5, H-5 with H-7, and H-7 with H-9 showed that the corresponding groups are on the α-face. NOESY correlation of H-15/H-14 supported the conclusion that the C13–C15 double bond is in the Z-form. Consequently, the structure of 4 was unambiguously established, and the compound has been named norerythrofordin A. In our search of previous publications regarding cassaine-type diterpenoids, 4 was found to be a new skeleton with only 19 carbons. A plausible biogenetic pathway to norerythrofordin A (4) would occur through decarboxylation of erythrofordin A (1).

In addition, 27 known compounds were identified by comparison of their physical and spectroscopic data with those of corresponding authentic samples or literature values. These compounds are triterpenoids 5–17 [β-amyrine (5), 8 β-amyrin acetate (6), 9 cycloartenol (7), 10 cycloart-25-en-3-one (8), 11 3,31,33,36-tetraoolean-12-ene-30-oic acid (9), 12 friedelin (10), 13 glutin-5-en-3-β-ol (11), 14 glutin (11), 15 luteolin (12), 16 squalene (12), 17 squalene (13), 18 taraxerone (13), 19 5-stigmasten-3β,7-diol (18), 20 5,8-stigmasta-7,22-diene-3β-ol (19), 21 5-stigmast-3β,7-diol (20), 22 5β-sitosterol (21), 23 and stigmasteryl (22), 24 as well as 23–31 [loilolide (23), 24 azulene (24), 25 blumenol (25), 26 echinol (26), 27 ericolid (27), 28 lutein (28), 29 [3S,5R,6R,7E,9R]-megastigman-7-ene-3,5,6,9-tetraol (29), 30 o-pinitol (30), 31 and α(+)-sucrose (31)].

### 3. Anti-inflammatory activities

#### 3.1. Effects of tested compounds on NADPH oxidase (NOX) and nitric oxide synthase (NOS) activity in murine microglial cells

Activated microglial cells play deleterious roles in mediating central nervous system (CNS) inflammatory responses by producing enormous amounts of NO and ROS through induction of inducible nitric oxide synthase (iNOS) and activation of NOX, which results in neuronal damage by NO, ROS, and the more toxic metabolite peroxynitrite (ONOO⁻). 32–35 We also reported that drugs with antioxidant and NO-reducing activity can prevent stroke-induced brain damage. 34 Therefore, inhibiting NO or ROS production is a useful

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effects of tested compounds on NADPH oxidase (NOX) and nitric oxide synthase (NOS) activity in murine microglial cells</td>
</tr>
<tr>
<td>Compound</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>11</td>
</tr>
<tr>
<td>12</td>
</tr>
<tr>
<td>13</td>
</tr>
<tr>
<td>16</td>
</tr>
<tr>
<td>17</td>
</tr>
<tr>
<td>18</td>
</tr>
<tr>
<td>19</td>
</tr>
<tr>
<td>20</td>
</tr>
<tr>
<td>24</td>
</tr>
<tr>
<td>25</td>
</tr>
<tr>
<td>26</td>
</tr>
<tr>
<td>27</td>
</tr>
<tr>
<td>29</td>
</tr>
<tr>
<td>30</td>
</tr>
<tr>
<td>DPI</td>
</tr>
<tr>
<td>L-NAME</td>
</tr>
</tbody>
</table>

*NOX and NOS activities were measured as ROS and NO production, respectively, in the presence of 0.1–50 μM of drugs. DPI (diphenyleneiodonium, an NOX inhibitor) and L-NAME (a NOS inhibitor) were included as positive control. Data were calculated as %inhibition or 50% inhibitory concentration (IC50) and expressed as means ± SEM from 3–6 experiments performed on different days using cells from different passage. *P < 0.05 as compared with relative positive control (DPI or L-NAME), respectively. **ND**: value not determined.
strategy for treating inflammatory disorders, such as cardiovascular diseases and neurodegenerative disorders. The anti-inflammatory potentials of 4–6, 10–13, 16–20, 24–27, 29 and 30 were evaluated by examining their effects on LPS-induced iNOS-dependent NO production and NOX-dependent ROS production in microglial cells. Only taxaraxerol (16) showed effectively inhibited NOS activity with an IC50 value of 24.2 μM. Its potency was comparable to that of L-NAME (IC50 25.8 μM), a specific NOS inhibitor. NOX is the major ROS-producing enzyme in activated inflammatory cells.36 We previously reported that drugs with anti-inflammatory activity also show potent NOX-inhibitory action.37,38 Therefore, we also evaluated the above compounds on NOX activity in lysates of microglial cells. Our data suggest that gallic acid (27) and (35SR,6SR,7SR)-megastigma-7-ene-3,5,6,9-tetralol (29) (maximum inhibition of NOX activity at 50 μM ranging from 21% to 25%) are ordinary inhibitors of NOX, as compared to the specific NOX inhibitor DPI (IC50 16 μM). Moreover, compounds 11, 12, 16, 18, 25, and 30 showed only slight (10.8–19.2%) inhibition of NOX activity.

3.2. Measurement of 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical-scavenging capacity

The free radical-scavenging capacities of 4–6, 10–13, 16–20, 24–27, 29 and 30 were examined in a cell-free DPPH solution. Only gallic acid (27) showed activity in this assay, with 85.6% maximum radical-scavenging capacity at 50 μM, as compared to 85.7% for the positive control trolox (data not shown).

4. Conclusion

Four new compounds were isolated and identified from E. fordii, together with 27 known compounds. Bioassay results indicated that taxaraxerol (16) displays potent NO-reducing activity in microglial cells and gallic acid (27) exhibits excellent DPPH radical-scavenging effects.

5. Experimental

5.1. General experimental procedures

Melting points were determined using Yanagimoto MP-S3 micro melting point apparatus and are uncorrected. Optical rotations were measured using a JASCO DIP-370 digital polarimeter. UV spectra were recorded on a Hitachi U-3210 spectrophotometer, IR spectra were recorded on a Shimadzu FT-IR Prestige-21 spectrophotometer. 1H- and 13C-NMR, COSY, HMOC, HMBC, and NOESY spectra were recorded on Bruker AVANCE-300, 500 and AMX-400 spectrometers, using tetramethylsilane (TMS) as internal standard. Standard pulse sequences and parameters were used for the NMR experiments and all chemical shifts are reported in parts per million (ppm, δ). FABMS were obtained on a JEOL JMS-700 spectrometer, and EIMS were obtained on a VG-70-250S spectrometer. Column chromatography was performed on silica gel (70–230 mesh, 230–400 mesh). Fractions were monitored by TLC (Merck precoated Si gel 60 F 254 plates), using UV light. TLC was conducted on precoated Kieselgel 60 F 254 plates (Merck) and the spots were detected either by examining the plates under a UV lamp or by treating the plates with a 10% methanolic solution of p-anisaldehyde acid followed by heating at 110°C.

5.2. Plant material

The whole plant of E. fordii (Leguminosae) was collected near Hanoi in Vietnam on Nov 12 in 2004. The plant material was identified and authenticated by Assoc. Prof. Dr. Vu Xuan Phuong, Institute of Ecology and Biological Resources, Vietnamese Academy of Science and Technology. A voucher specimen (EF04021) has been deposited in the herbarium of the Institute of Ecology and Biological Resources, Vietnamese Academy of Science and Technology, Hanoi, Vietnam.

5.3. Extraction and Isolation

The air-dried and powdered whole plant of E. fordii (10 kg) was extracted with MeOH (6 × 20 L) at room temperature. The filtrate was concentrated under reduced pressure to obtain a dark crude extract (890 g), which was suspended in H2O, then partitioned with CHCl3 to afford CHCl3 (340 g) and H2O-soluble portions (480 g), respectively.

The CHCl3-soluble residue (340 g) was chromatographed on a silica gel column eluting with stepwise gradient mixtures of CHCl3–MeOH (9:1 to 0:1) to afford six fractions (1–6). Subfraction 1 was further subjected to column chromatography over silica gel using a stepwise gradient of n-hexane-acetone (3:2–0:1) and purified by repeated column chromatography to afford 5 (4.1 mg), 6 (4.1 mg), 8 (1.1 mg), 10 (47.8 mg), 11 (20.7 mg), 12 (24.9 mg), 13 (14.3 mg), 14 (0.9 mg), 15 (1.2 mg), 16 (30.1 mg), 17 (27.6 mg), 19 (34.7 mg), 21 (51.0 mg), and 22 (49.0 mg). Fraction 2 was subjected to silica gel column chromatography using n-hexane-acetone (3:2–0:1) stepwise gradient mixtures as eluents to afford 7 (0.6 mg), 18 (23.8 mg), 20 (10.2 mg), 23 (0.7 mg), 26 (2.3 mg), and 28 (14.3 mg). Purification of fraction 3 by silica gel column chromatography with n-hexane-acetone (2:1–0:1) stepwise gradient mixtures as eluents followed by preparative thin-layer chromatography afforded 1 (0.8 mg), 2 (0.7 mg), 3 (0.6 mg), 4 (1.2 mg), and 25 (0.3 mg). Further purification of fraction 4 by column chromatography over silica gel with mixed eluents of diisopropyl ether–MeOH (9:1–0:1) and repeated column chromatography and thin-layer chromatography gave compounds 27 (54.8 mg), 24 (11.1 mg), and 29 (0.3 mg). Fraction 5 was further subjected to column chromatography over silica gel using a stepwise gradient of diisopropyl ether–MeOH (9:1–0:1) and preparative thin-layer chromatography purification to afford 30 (45.2 mg), and 31 (1.0 mg). Subfraction 6 was further subjected to column chromatography over silica gel using a stepwise gradient of acetone–MeOH (2:1–0:1) to afford 9 (0.8 mg).

5.3.1. Erythrofordin A (1)

Colorless powder, mp 138–139°C; χp,20 = –32.3 (c 0.05, CH3OH); UV (MeOH) λmax (log ε) 219 (3.98) nm; IR (KBr) υmax 3381 (OH), 1720 (C=O), 1679 (C=O), 1642 (CO) cm–1; 1H NMR (CDCl3, 400 MHz) δ 7.77 (1 H, d, J= 1.4 Hz, H-15), 3.93 (1 H, d, J= 10.6 Hz, H-7), 3.77 (1 H, br s, H-14), 2.95 (3 H, s, D2O-exchangeable, 0-H3), 3.76 (3 H, s, D2O-exchangeable, 0-H7), 3.68 (1 H, br s, D2O-exchangeable, 0-H5), 3.48 (1 H, br s, D2O-exchangeable, 0-H3), 3.48 (1 H, dd, J=11.6, 4.2 Hz, H-3), 2.85 (1 H, s, m, H-14), 2.34 (1 H, s, H-5), 2.32 (1 H, m, H-12), 2.28 (1 H, m, H-2), 2.10 (1 H, m, H-12), 2.01 (1 H, br s, H-11), 1.91 (1 H, m, H-11), 1.88 (1 H, m, H-2), 1.74 (1 H, m, H-11), 1.72 (1 H, m, H-1), 1.69 (1 H, m, H-8), 1.65 (1 H, m, H-9), 1.55 (1 H, m, H-12), 1.51 (1 H, m, H-1), 1.37 (3 H, s, H-18), 1.18 (3 H, d, J= 8.8 Hz, H-17), 0.67 (3 H, s, H-20); 13C NMR (CDCl3, 100 MHz) δ 207.8 (C-1), 174.2 (C-19), 169.5 (C-18), 137.2 (C-14), 74.3 (C-13), 71.8 (C-17), 71.6 (C-16), 71.3 (C-15), 71.2 (C-14), 71.1 (C-13), 71.0 (C-12), 70.9 (C-11), 70.8 (C-10), 70.7 (C-9), 70.6 (C-8), 70.5 (C-7), 70.4 (C-6), 70.3 (C-5), 70.2 (C-4) ppm. HRMS (EI, m/z 395.2068 [M + H]+); HRFABMS m/z 395.2068 [M + H]+ (calcd for C21H31O7, 395.2070).

5.3.2. Erythrofordin B (2)

Colorless syrup; χp,20 = –36.6 (c 0.01, CH3OH); UV (MeOH) λmax (log ε) 217 (4.23) nm; IR (KBr) υmax 3379 (OH), 1716 (C=O), 1640 (C=O) cm–1; 1H NMR (CD3OD, 300 MHz) δ 5.60 (1 H, s, H-15), 4.26 (1 H, m, H-14), 4.03 (1 H, d, J= 9.7 Hz, H-7), 3.66 (3 H, s, H-21),
3.41 (1 H, dd, J = 11.7, 4.2 Hz, H-3), 2.58 (1 H, s, H-5), 2.47 (1 H, td, J = 13.3, 3.7 Hz, H-12x), 2.18 (1 H, m, H-23), 2.15 (1 H, m, H-12x), 1.95 (3 H, s, H-23), 1.95 (1 H, m, H-11), 1.79 (1 H, m, H-11b), 1.77 (1 H, m, H-8), 1.76 (1 H, m, H-11), 1.75 (1 H, m, H-9), 1.62 (1 H, dd, J = 13.2, 3.6 Hz, H-2x), 1.41 (1 H, m, H-1x), 1.27 (3 H, s, H-18), 1.17 (3 H, d, J = 7.0 Hz, H-17), 0.95 (3 H, s, H-20); 13C NMR (CD3OD, 75 MHz) δ 210.6 (C-6), 177.5 (C-22), 175.8 (C-19), 171.2 (C-16), 164.3 (C-13), 115.9 (C-15), 78.4 (C-3), 77.2 (C-7), 65.3 (C-5), 51.9 (C-21), 51.3 (C-8), 47.6 (C-9), 46.6 (C-4), 43.4 (C-10), 37.8 (C-1), 32.9 (C-12), 32.4 (C-14), 28.1 (C-11), 28.0 (C-2), 26.2 (C-18), 22.2 (C-23), 14.9 (C-20), 13.3 (C-17); FABMS m/z 437 [M + H]+; HRFABMS m/z 437.2175 [M + H]+ (calcd for C23H30O6, 437.2177).

5.3.3. Erythroxilin C (3)

Colorless syrup; λmax (log ε) 284 (4.25) nm; IR (KBr) νmax 3418 (OH), 1702 (CO), 1645 (CO) cm⁻¹; 1H NMR (DMSO-d6, 300 MHz) δ 11.95 (1 H, s, 16-COOH), 5.57 (1 H, s, H-15), 4.83 (1 H, d, J = 5.9 Hz, D2O-exchangeable, OH-7), 4.45 (1 H, d, J = 6.8 Hz, D2O-exchangeable, OH-5), 3.96 (1 H, m, H-7), 3.65 (1 H, m, H-15), 2.91 (1 H, m, H-3), 2.67 (1 H, m, H-14), 2.17 (1 H, d, J = 4.6 Hz, H-5), 1.93 (1 H, m, H-12x), 1.90 (1 H, m, H-11), 1.88 (1 H, m, H-9), 1.76 (1 H, m, H-11x), 1.65 (1 H, m, H-2x), 1.62 (1 H, m, H-4), 1.58 (1 H, m, H-8), 1.28 (2 H, m, H-11 and H-20); 0.83 (3 H, s, H-9), 0.84 (3 H, d, J = 6.0 Hz, H-18), 0.51 (3 H, s, H-19); 13C NMR (DMSO-d6, 75 MHz) δ -210.2 (C-6), 167.6 (C-16), 165.1 (C-13), 113.4 (C-15), 75.2 (C-7), 73.9 (C-3), 59.2 (C-5), 51.8 (C-8), 43.0 (C-9), 41.7 (C-10), 39.2 (C-14), 36.2 (C-1), 33.4 (C-4), 30.2 (C-2), 26.2 (C-11), 23.4 (C-12), 16.2 (C-18), 13.3 (C-17 and C-19); EIMS m/z 336 [M]+; HREIMS m/z 336.1933 [M]+ (calcd for C19H26O8S, 336.1937).

5.4. Anti-inflammatory activities

5.4.1. Measurement of 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical-scavenging capacity

DPPH radical-scavenging capacity assay was performed as in our previous report.[37]

5.4.2. Microgel cell culture and measurements of nitric oxide (NO)

The murine microgel cell line (BV2) was cultured and production of NO was measured by the methods as described in our prior report.[34]